JANUX THERAPEUTICS
Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response.
JANUX THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Diagnostics Pharmaceutical Therapeutics
Founded:
2017-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.januxrx.com
Total Employee:
11+
Status:
Active
Contact:
858-750-4700
Total Funding:
192.44 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Radius Health
Radius Health develops drug therapies for osteoporosis and women’s health.
Current Employees Featured
Founder
Stock Details
Investors List
OrbiMed
OrbiMed investment in Series B - Janux Therapeutics
BVF Partners
BVF Partners investment in Series B - Janux Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Janux Therapeutics
Samsara BioCapital
Samsara BioCapital investment in Series B - Janux Therapeutics
Hartford HealthCare Endowment
Hartford HealthCare Endowment investment in Series B - Janux Therapeutics
Bregua Corporation
Bregua Corporation investment in Series B - Janux Therapeutics
EcoR1 Capital
EcoR1 Capital investment in Series B - Janux Therapeutics
Logos Capital
Logos Capital investment in Series B - Janux Therapeutics
Surveyor Capital
Surveyor Capital investment in Series B - Janux Therapeutics
Avalon Ventures
Avalon Ventures investment in Series B - Janux Therapeutics
Key Employee Changes
Official Site Inspections
http://www.januxrx.com Semrush global rank: 4.53 M Semrush visits lastest month: 2.33 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Janux Therapeutics"
Janux | T Cell Immunotherapy for Cancer
Janux is developing novel immunotherapies to stimulate the immune system without causing systemic safety issues to fight cancer and autoimmune diseases.See details»
Janux Therapeutics - 2025 Company Profile & Team - Tracxn
5 days ago Janux Therapeutics - Developer of immunotherapeutics for the treatment of cancer. Public Company. Raised a total funding of $181M over 2 rounds from 12 investors.See details»
Janux Therapeutics (JANX) Company Profile, History, Products
Company Overview Janux Therapeutics, Inc. (NASDAQ: JANX) is a clinical-stage biopharmaceutical company focused on developing novel T cell engager immunotherapies for …See details»
Janux Therapeutics
Aug 10, 2025 Janux Therapeutics was founded in 2019 with the goal of revolutionizing the treatment of cancer and other diseases. We are focused on discovering, developing and …See details»
Overview, News & Similar companies - ZoomInfo.com
May 8, 2024 View Janux Therapeutics (www.januxrx.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
Janux Therapeutics - Crunchbase Company Profile
Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.See details»
Janux Therapeutics | Novel T Cell Immunotherapies
Janux Therapeutics is precision engineering novel immunotherapies to fight cancer and autoimmune disease by selectively modulating T cells without …See details»
Janux Therapeutics Org Chart + Executive Team
The org chart of Janux Therapeutics contains its 28 main executives like David Campbell, Andy Meyer and James Pennington.See details»
Janux Therapeutics Company Overview, Contact Details
Dec 3, 2024 Learn more about Janux Therapeutics's company details, contact information, competitors, and more. Find accurate contact data easily with LeadIQ. Book a demo today.See details»
Janux Therapeutics - LinkedIn
Janux Therapeutics | 9,225 followers on LinkedIn. Janux is a clinical-stage company developing unique immunotherapies that have the potential to generate tumor-specific immune responses …See details»
Janux Therapeutcs | Novel T Cell Immunotherapy | Leadership
Learn about the leadership of Janux, a company developing novel immunotherapies that selectively modulat T cells to fight cancer and autoimmune diseases.See details»
Janux Therapeutics | Novel T Cell Immunotherapy | Contact
With its headquarters in San Diego, CA, Janux is a clinical-stage biopharmaceutical company developing a broad pipeline of novel T cell immunotherapies.See details»
Janux - Investor Relations - About Us - Go Daddy
Janux - Investor Relations - About UsSee details»
Janux - Investor Relations - Investors & Media
Jul 24, 2025 Janux is a clinical-stage company developing precision-engineered immunotherapies that have the potential to generate potent and durable immune responses …See details»
Janux | Novel T Cell Immunotherapy | ARM Platform - januxrx.com
Janux is developing a novel class of adaptive response modulator (ARM) bispecifics to address clinically validated drug targets to fight autoimmune disease.See details»
Janux Therapeutics | T Cell Immunotherapy | Our Culture
Get to know the culture at Janux Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of novel T cell immunotherapies.See details»
Janux - Investor Relations - Janux Therapeutics Reports First …
May 8, 2025 Phase 1b expansion study initiated with JANX007 in taxane-naïve mCRPC patients Updated JANX007 data from Phase 1a dose escalation support initiation of Phase 1b dose …See details»
Janux - Investor Relations - About Us - Go Daddy
Janux - Investor Relations - About UsSkip to main contentSee details»
David Campbell, Ph.D. - Janux Therapeutics
David founded Janux in 2017 to develop tumor-specific cancer therapeutics in order to improve patient safety and efficacy for this important class of drugs. David brings more than 25 years of …See details»
Janux - Investor Relations - Janux Therapeutics Announces Clinical ...
Aug 5, 2025 First patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage …See details»